Deferasirox (ICL 670) 是具有口活性的，可用于铁离子过量的螯合剂。

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.

Solid

In LX-2 cells treated with 50?μM deferasirox for 12?h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120?h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner. has not independently confirmed the accuracy of these methods. They are for reference only.

The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45.
[2]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5.

In Vitro: DMSO : ≥ 100 mg/mL (267.84 mM)配制储备液